How Long Do Antivirals Stay in Your System?

Most antivirals clear from your bloodstream within a day or two, but the full range spans from a few hours to several months depending on the specific drug, its formulation, and your body’s ability to break it down. A standard course of oseltamivir (Tamiflu) for influenza, for instance, leaves the blood within roughly a day of the last dose. An injectable long-acting HIV prevention drug like cabotegravir can remain detectable for well over a year after the final shot. Understanding where a particular antiviral falls on that spectrum matters for everything from timing your next medication to managing side effects and avoiding drug interactions.

The Half-Life Principle

Every drug leaves the body in a predictable pattern governed by its half-life, which is the time it takes for half of the drug to be eliminated. After one half-life, half the dose remains; after two half-lives, a quarter remains; after three, an eighth; and so on. Pharmacologists generally consider a drug “out of your system” after about five half-lives, by which point over 96 percent of it is gone.¹ For a drug with a two-hour half-life, that means roughly ten hours. For a drug with a half-life measured in days or weeks, the timeline stretches accordingly.

Antivirals cover an enormous range of half-lives. Some are designed to be taken multiple times a day because they clear so quickly. Others are engineered to persist, either through slow-release formulations or because the active compound lodges inside cells and keeps working long after blood levels drop. The half-life you see on a drug label usually refers to plasma (blood) levels, but as we’ll see, what’s happening inside specific tissues can be a different story.

Common Antivirals and How Quickly They Clear

If you’ve taken an antiviral for the flu, a herpes outbreak, or COVID-19, you’ve probably wondered how long it lingers. Here are some of the most widely prescribed antivirals and their approximate clearance timelines, based on their known half-lives and the five-half-life rule.

• Oseltamivir (Tamiflu): The active form, oseltamivir carboxylate, has a plasma half-life of about six to ten hours. That puts full clearance at roughly two days after your last dose. Because it’s water-soluble in its active form, it doesn’t tend to accumulate in fat tissue.
• Acyclovir and valacyclovir: Acyclovir, used for herpes simplex and varicella-zoster infections, has a half-life of about two to three hours in adults with normal kidney function. Valacyclovir converts to acyclovir in the body, so the clearance timeline is similar. Kidney filtration rate is the main factor that determines how quickly acyclovir leaves.² Five half-lives puts clearance at about ten to fifteen hours in a healthy adult.
• Nirmatrelvir/ritonavir (Paxlovid): Nirmatrelvir, the component that blocks SARS-CoV-2 replication, has a half-life of roughly six to seven hours. The ritonavir in each dose slows down the liver enzymes that would otherwise break nirmatrelvir down too quickly, effectively keeping it active longer.³ After the five-day course ends and you stop taking ritonavir too, nirmatrelvir clears within about a day and a half.
• Tenofovir (as TDF or TAF): Tenofovir in plasma has a relatively short half-life of about 15 hours, and a sensitive urine test can detect the most recent dose for roughly two to seven days.⁴ But inside cells, tenofovir diphosphate (the active form) has a much longer intracellular half-life, which is why it can be dosed once daily for HIV prevention or treatment.

These numbers assume healthy adults with normal organ function. As you’ll see, several common conditions can shift them substantially.

Kidney and Liver Function Change the Math

Your kidneys and liver are the two main exit routes for drugs. Many antivirals depend heavily on one or the other, and when either organ isn’t working well, the drug hangs around longer than expected.

Acyclovir and its relatives are cleared almost entirely by the kidneys. In older adults or anyone with chronic kidney disease, a standard dose can produce blood levels far higher than intended. A study of older adults with kidney disease found that higher-dose herpes antivirals carried a nearly four-fold increase in the risk of acute kidney injury compared with lower doses, though the absolute risk remained under one percent.⁵ The same principle applies to several hepatitis B antivirals, which are excreted through urine and may need dose reductions when kidney function declines.⁶

Liver metabolism is the main clearance pathway for most HIV protease inhibitors and many hepatitis C drugs. The enzyme CYP3A4, which handles an estimated 40 percent of all marketed drugs, plays a central role in breaking down these antivirals.⁷ When liver disease reduces CYP3A4 activity, these drugs accumulate. Interestingly, hepatitis C infection itself can alter drug metabolism: research using human liver cells showed that the virus activates a receptor called PXR, which in turn ramps up CYP3A4 activity by several fold, potentially speeding up drug clearance during the very infection being treated.⁸ This is an unusual case where the virus itself changes how fast the body clears the antiviral.

For hepatitis C direct-acting antivirals, patients with liver impairment generally tolerate them at standard doses because most are not cleared by the kidneys. Kidney-impaired patients, however, may struggle with ribavirin even after dose adjustments, and certain combinations need to be chosen carefully based on how severe the kidney disease is.⁹

Age, Body Weight, and Pregnancy

Getting older affects antiviral clearance even when your organs are technically healthy. Modeling based on clinical data for HIV antiretrovirals estimated that the natural decline in drug clearance over a lifetime can increase overall drug exposure by as much as 70 percent between young adulthood and old age.¹⁰ That’s not because older people take more of the drug; it’s because their bodies process it more slowly. Both liver and kidney function tend to decline with age, compounding the effect.¹¹

Body composition matters too. Fat-soluble drugs tend to distribute into a larger volume in people with higher body fat, which can mean lower peak blood concentrations but potentially slower overall clearance as the drug trickles back out of fatty tissue. Oseltamivir is lipophilic (fat-attracted) in its prodrug form, so researchers expected it to distribute more widely in obese individuals, though the active metabolite is water-soluble and behaves differently.¹² The practical takeaway: body weight can shift how a drug distributes and how long it takes to wash out completely, but the direction depends on whether the specific drug loves fat or water.

Pregnancy introduces yet another variable. The body undergoes dramatic changes in blood volume, kidney filtration rate, and liver enzyme activity during pregnancy, all of which alter drug clearance. Research on hepatitis C direct-acting antivirals found that exposure to these drugs is likely altered during pregnancy, mostly related to changes in absorption and metabolism.¹³ In many cases, faster clearance during pregnancy means lower drug levels, which could affect how well the antiviral works if the dose isn’t adjusted.

Drug Interactions That Extend Clearance

One of the most striking ways an antiviral’s time in your system gets extended is through deliberate drug interactions. The clearest example is ritonavir, a protease inhibitor originally developed for HIV but now used mainly as a pharmacokinetic booster. Ritonavir powerfully inhibits CYP3A4, the liver enzyme responsible for metabolizing most HIV protease inhibitors. When given alongside another protease inhibitor, ritonavir slows the second drug’s breakdown, increasing its peak levels, trough levels, and effective half-life.¹⁴ This is the same principle behind Paxlovid: the ritonavir keeps nirmatrelvir active longer than it would last on its own.

The flip side is that anything else competing for CYP3A4 can get caught up in the traffic jam. If you’re taking an antiviral that’s metabolized by CYP3A4 alongside another medication processed by the same enzyme, both drugs may clear more slowly. Hepatitis C antivirals like asunaprevir, daclatasvir, and beclabuvir are all metabolized by CYP3A4 and transported by P-glycoprotein, meaning their clearance can be altered by a wide range of co-administered drugs.¹⁵ Your doctor or pharmacist checks for these interactions before prescribing, but it’s worth knowing why the question “what else are you taking?” matters so much for antivirals.

Blood Levels Don’t Tell the Whole Story

When we say a drug “stays in your system,” we usually mean it’s detectable in blood. But antivirals work inside specific tissues, and drug concentrations in those tissues can be very different from what a blood test shows. This gap has real consequences.

HIV antiretrovirals provide the most studied example. Researchers who measured drug levels in lymph node tissue found concentrations that were much lower than in the blood, and this correlated with ongoing low-level viral replication in those tissues even during treatment.¹⁶ In other words, the blood said “plenty of drug,” but the tissue where the virus actually lives said “not enough.” Drug penetration into the genital tract varies dramatically by drug class, with certain nucleoside analogues accumulating well in both seminal and cervicovaginal fluid, while protease inhibitors and efavirenz penetrate poorly.¹⁷

A similar pattern emerged during COVID-19 treatment research. Analysis of antiviral tissue distribution found that drugs which concentrated well in the lungs, like favipiravir, were reported to reduce viral loads in the respiratory tract, while drugs with poor lung distribution struggled to inhibit the virus there despite adequate blood levels.¹⁸ So “how long does it stay in your system” really depends on which part of your system you’re asking about. For some drugs, the active form persists inside target cells long after it’s undetectable in blood.

The experimental HIV drug islatravir illustrates the extreme end of this. Its active form, islatravir-triphosphate, had an intracellular half-life of about eight days inside immune cells, even though islatravir itself cleared from plasma with a half-life of about 73 hours.¹⁹ That long intracellular persistence is what makes extended dosing intervals possible for some newer antivirals.

Long-Acting Injectables and the Months-Long Tail

The newest frontier in antiviral pharmacology is drugs designed to stay in your system for weeks or months after a single injection. Cabotegravir, used for HIV prevention and treatment, is formulated as a slow-release intramuscular injection. After the final shot, the drug doesn’t simply vanish; it leaches out of the injection-site depot gradually.

In a clinical trial tracking how long cabotegravir remained detectable after participants stopped receiving injections, the median time to undetectable levels was about 44 weeks for men and 67 weeks for women. Some individuals still had detectable drug more than three years after their last injection. Women and people with higher body mass index tended to clear the drug more slowly.²⁰ This extremely long tail has implications for pregnancy as well: modeling work found that cabotegravir and rilpivirine pharmacokinetic tails extend several months into the postpartum period when given during pregnancy.²¹

The benefit is obvious: you don’t have to remember a daily pill. But the long tail creates a problem that doesn’t exist with short-acting drugs.

The Resistance Risk of a Long Pharmacokinetic Tail

When a drug clears quickly, it goes from effective levels to essentially zero in a matter of hours or days. There’s a brief window where concentrations are too low to suppress the virus but high enough to exert some selective pressure on it. With a short-acting drug, this window is narrow and typically harmless.

Long-acting injectables create a much wider window. Lenacapavir, another long-acting injectable for HIV, produces a “mutant selection window” lasting roughly 100 to 235 days after discontinuation, during which falling drug concentrations can favor the survival of partially resistant viral variants.²² In plain terms: the drug is still there, but not at high enough levels to fully suppress the virus, and any virus that happens to be slightly resistant gains an advantage during that period.

This is a genuine clinical concern for people who stop or switch long-acting prevention regimens. Clinicians typically plan a “bridging” strategy, starting oral antivirals before the injectable fully washes out so there’s never a prolonged sub-therapeutic window. It’s a problem that simply doesn’t arise when a drug clears in a day.

What Paxlovid Rebound Tells Us About Clearance

When Paxlovid became widely available for COVID-19, reports of “viral rebound” a few days after finishing the five-day course raised questions about whether the drug was leaving the body too quickly. The pattern was distinctive: symptoms improved during treatment, then returned after the final dose, sometimes accompanied by a positive test again.

Modeling work suggests the rebound isn’t really about clearance speed per se. Rather, when Paxlovid is started near the time symptoms appear, it effectively preserves the cells the virus infects. That’s good in the short term, because it prevents tissue damage and reduces symptoms. But if the virus hasn’t been entirely eliminated during the five-day course, the preserved cells give the virus something to infect once drug levels drop. Meanwhile, the adaptive immune response may be slightly delayed because the drug suppressed viral replication before the immune system had a chance to fully ramp up.²³

The same modeling work found that extending treatment to ten days might significantly reduce rebound in high-risk patients. And a CDC analysis of clinical trial data noted that viral RNA rebound during treatment (not just after) was common even in placebo recipients, suggesting that at least some rebound reflects natural variability in how the body sheds virus rather than a direct consequence of drug washout.²⁴ If you experienced Paxlovid rebound, it probably wasn’t because the drug left your body unusually fast. The five-day course may have simply been too short to finish the job for your particular infection.

Monitoring Adherence Through Drug Detection

For people taking daily antivirals for HIV prevention (PrEP) or chronic hepatitis B treatment, the question flips from “how long does it stay” to “can my doctor tell whether I’ve been taking it?” Drug monitoring is an increasingly practical tool, and how long the antiviral persists in detectable form determines which tests are useful.

Tenofovir provides a useful case study. Its plasma half-life is short enough that a blood or urine test primarily reflects very recent dosing. Sensitive urine assays can detect tenofovir from a dose taken as long as two to seven days ago, making it possible to roughly assess recent adherence in a clinic visit.⁴ But because tenofovir diphosphate accumulates inside red blood cells with a much longer intracellular half-life, dried blood spot testing can reflect adherence patterns over weeks, not just days. The two tests answer different questions: did you take your pill recently, versus have you been taking it consistently over the past month?

This distinction between short plasma half-life and long intracellular half-life is common among antivirals. It means a blood test can come back “undetectable” for the drug in plasma while therapeutic concentrations persist inside the cells where the drug actually works. For most people taking their medication as prescribed, the practical implication is reassuring: missing a single dose usually doesn’t create an immediate gap in protection, because the intracellular reservoir buys time. But stringing together multiple missed doses will eventually deplete that reservoir, and the plasma-based window of detection is too short to catch that pattern unless more sophisticated testing is used.